Journal: Frontiers in Immunology
Article Title: Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy
doi: 10.3389/fimmu.2025.1644391
Figure Lengend Snippet: Effects of anti-OX-40 mAbs on co-cultures of lymphocytes and tumor cells used alone or in combination with anti-PD-L1 mAbs. (A) IL-2 secretion in supernatants of hPBMCs treated with anti-OX-40 mAbs alone or combined with anti-PD-L1 mAb. IL-2 levels were measured by following the manufacturer’s recommendations of cytokines secretion kit by R & D Systems. (B) Analysis of OX-40 and PD-L1 expression on different tumor cell lines by cell ELISA. (C) Tumor cell lysis induced by OX-40 mAbs alone or in combination with anti-PD-L1 mAbs on co-cultures of MDA-MB-231 tumor cells with unfractionated hPBMCs (left) or NK cells (right). The results were obtained by at least three independent experiments. Error bars depicted means ± SD and The P values reported are: ***P < 0.001; **P < 0.01; * ≤ 0.05, by student’s t test (two variables), calculated by comparing the combinations with each respective compound used as a single agent.
Article Snippet: The clinically validated anti-PD-L1 Atezolizumab mAb (N298A, InvivoGen) and anti-OX-40 Rocatinlimab (HY-P99955, MedChemExpress) were also used.
Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Lysis